
Viveve Medical VIVE
Quarterly report 2022-Q3
added 11-10-2022
Viveve Medical Accounts Receivables 2011-2026 | VIVE
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 549 K | 770 K | 1.57 M | 5.7 M | 6.21 M | 2.09 M | 593 K | 6 K | 502 K | 402 K | 453 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.71 M |
Quarterly Accounts Receivables Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 860 K | 801 K | 509 K | 549 K | 514 K | 696 K | 336 K | 770 K | 770 K | 770 K | 770 K | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 6.21 M | 6.21 M | 6.21 M | 6.21 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 593 K | 593 K | 593 K | 593 K | 6 K | 6 K | 6 K | 6 K | 502 K | 488 K | 210 K | 502 K | 402 K | 402 K | 402 K | 402 K | 453 K | 453 K | 453 K | 453 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.21 M | 6 K | 1.64 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
566 M | $ 39.19 | -0.73 % | $ 5.84 K | ||
|
Align Technology
ALGN
|
996 M | $ 185.52 | -0.54 % | $ 13.9 B | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 12.57 | -0.67 % | $ 1.7 B | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
Cytosorbents Corporation
CTSO
|
7.55 M | $ 0.6 | 1.51 % | $ 37.3 M | ||
|
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.51 | -0.28 % | $ 131 M | ||
|
LENSAR
LNSR
|
6.38 M | $ 5.92 | -5.28 % | $ 70.8 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | ||
|
ClearPoint Neuro
CLPT
|
6.55 M | $ 10.51 | 0.43 % | $ 298 M | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
24.7 M | $ 25.32 | -1.52 % | $ 214 M | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
178 K | $ 2.7 | -1.46 % | $ 7.49 M | ||
|
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | ||
|
Stryker Corporation
SYK
|
4.04 B | $ 337.97 | -0.96 % | $ 129 B | ||
|
Tactile Systems Technology
TCMD
|
43.9 M | $ 24.99 | -1.42 % | $ 572 M | ||
|
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 16.69 | -6.5 % | $ 392 M | ||
|
Globus Medical
GMED
|
679 M | $ 92.86 | -1.79 % | $ 12.6 B | ||
|
TELA Bio
TELA
|
10.3 M | $ 0.7 | 6.17 % | $ 32.9 M | ||
|
Helius Medical Technologies
HSDT
|
117 K | $ 2.02 | 3.87 % | $ 1.23 M | ||
|
Butterfly Network
BFLY
|
20.8 M | $ 5.27 | 8.44 % | $ 1.12 B | ||
|
Tandem Diabetes Care
TNDM
|
165 M | $ 20.09 | -2.76 % | $ 1.37 B | ||
|
Inogen
INGN
|
38.9 M | $ 6.52 | 5.16 % | $ 173 M | ||
|
IRIDEX Corporation
IRIX
|
7.61 M | $ 1.03 | -0.48 % | $ 17.4 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 10.84 | -1.36 % | $ 388 M | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 57.06 | 0.74 % | $ 1.68 B | ||
|
CONMED Corporation
CNMD
|
248 M | $ 38.16 | -3.25 % | $ 1.18 B | ||
|
LivaNova PLC
LIVN
|
216 M | $ 65.03 | -0.17 % | $ 3.55 B | ||
|
Integer Holdings Corporation
ITGR
|
346 M | $ 88.6 | 0.75 % | $ 3.08 B |